Dipeptidyl peptidase IV inhibition alters the hemodynamic response to angiotensin-converting enzyme inhibition in humans with the metabolic syndrome.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

10 citing papers in PubMed.

1. Antin-diabetic cognitive dysfunction effects and underpinning mechanisms of phytogenic bioactive peptides: a review.Frontiers in nutrition · 2024
   Review
2. Beneficial Effects of Dipeptidyl Peptidase-4 Inhibitors on Heart Failure With Preserved Ejection Fraction and Diabetes.JACC. Asia · 2023
   Article
3. Pharmacology of dipeptidyl peptidase-4 inhibitors and its use in the management of metabolic syndrome: a comprehensive review on drug repositioning.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2019
   Review
4. The pleiotropic cardiovascular effects of dipeptidyl peptidase-4 inhibitors.British journal of clinical pharmacology · 2018
   Review
5. Cut to the chase: a review of CD26/dipeptidyl peptidase-4's (DPP4) entanglement in the immune system.Clinical and experimental immunology · 2016
   Review
6. Pleiotropic effects of the dipeptidylpeptidase-4 inhibitors on the cardiovascular system.American journal of physiology. Heart and circulatory physiology · 2014
   Review
7. The gut-renal axis: do incretin-based agents confer renoprotection in diabetes?Nature reviews. Nephrology · 2014
   Review
8. Cardiovascular effects of gliptins.Nature reviews. Cardiology · 2013
   Review
9. Pharmacology of dipeptidyl peptidase-4 inhibitors: similarities and differences.Drugs · 2011
   Review
10. Effect of Dipeptidyl Peptidase 4 Inhibitors on Cardiovascular Events in Type-2 Diabetes Patients with Renal Impairment: A Systematic Review and Meta-analysis.Indian journal of endocrinology and metabolism
    Article

Corrections and comments

• Comment on
  Interactive hemodynamic effects of dipeptidyl peptidase-IV inhibition and angiotensin-converting enzyme inhibition in humans.2010

Authors and funding

1 author.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as